Prognostic Significance of Pretreatment 18 FALF-NOTA-FAPI-04 PET/CT in Patients With Recurrent Gastric Cancer Undergoing Combined PD-1 Inhibitor and Chemotherapy | Synapse
February 27, 2026Open Access
Prognostic Significance of Pretreatment 18 FALF-NOTA-FAPI-04 PET/CT in Patients With Recurrent Gastric Cancer Undergoing Combined PD-1 Inhibitor and Chemotherapy
Key Points
To explore the predictive value of [¹⁸F]ALF-NOTA-FAPI-04 PET/CT in assessing outcomes for patients with recurrent gastric cancer treated with PD-1 inhibitors and chemotherapy.
Used [¹⁸F]ALF-NOTA-FAPI-04 PET/CT imaging before treatment.
Monitored clinical outcomes during and after combined PD-1 inhibitor and chemotherapy.
Analyzed the imaging results to determine their correlation with patient outcomes.
The imaging tool demonstrated potential for predicting treatment responses.
Patients showing positive imaging results had better clinical outcomes.
The study suggests improved prognostic evaluation based on imaging findings.
Abstract
¹⁸FALF-NOTA-FAPI-04 PET/CT may be a useful imaging tool for predicting clinical outcomes in patients with recurrent gastric cancer undergoing treatment with PD-1 inhibitors and chemotherapy.